<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEN23723-S4L-2W-4NY"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 S3330 IS: To require the Secretary of Labor to conduct a study on the fiduciary duties of pharmacy benefit managers.</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2023-11-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>118th CONGRESS</congress><session>1st Session</session><legis-num>S. 3330</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20231115">November 15, 2023</action-date><action-desc><sponsor name-id="S397">Mr. Braun</sponsor> (for himself, <cosponsor name-id="S388">Ms. Hassan</cosponsor>, <cosponsor name-id="S411">Mr. Marshall</cosponsor>, <cosponsor name-id="S417">Mr. Budd</cosponsor>, and <cosponsor name-id="S362">Mr. Kaine</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To require the Secretary of Labor to conduct a study on the fiduciary duties of pharmacy benefit managers.</official-title></form><legis-body><section id="id463009c611164a16835f5276140e9204" section-type="section-one"><enum>1.</enum><header>Study on fiduciary duties of pharmacy benefit managers</header><subsection commented="no" display-inline="no-display-inline" id="idb8be734679334ca6b4d7e45c8c3d496b"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 2 years after the date of enactment of this Act, the Secretary of Labor shall conduct, and submit to Congress a report describing the results of, a study on the impacts of a change in policy described in subsection (b). </text></subsection><subsection commented="no" display-inline="no-display-inline" id="idddafa8f004a144ac8c6672bd5ba3f6bf"><enum>(b)</enum><header>Policy described</header><text display-inline="yes-display-inline">Under a policy referred to in subsection (a)—</text><paragraph commented="no" display-inline="no-display-inline" id="ided8141b61dc6474e9efb2afe3f49b74c"><enum>(1)</enum><text display-inline="yes-display-inline">an entity providing pharmacy benefit management services would be considered a fiduciary within the meaning of section 3(21) of the Employee Retirement Income Security Act of 1974 (<external-xref legal-doc="usc" parsable-cite="usc/29/1002">29 U.S.C. 1002(21)</external-xref>) with respect to a group health plan or group health insurance coverage;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3c42b7501a8e4e81aa5310387c5f30fe"><enum>(2)</enum><text display-inline="yes-display-inline">such an entity would—</text><subparagraph commented="no" display-inline="no-display-inline" id="id62fd714c31864bce86c4e65aeb157fb5"><enum>(A)</enum><text display-inline="yes-display-inline">be subject to the responsibilities, obligations, and duties imposed on fiduciaries under part 4 of subtitle B of title I of such Act (<external-xref legal-doc="usc" parsable-cite="usc/29/1101">29 U.S.C. 1101 et seq.</external-xref>); and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id638c452800d7457aabfd254cd4bb0d7d"><enum>(B)</enum><text display-inline="yes-display-inline">make the required fiduciary disclosure under section 408(b)(2)(B)(iii) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/29/1108">29 U.S.C. 1108(b)(2)(B)(iii)</external-xref>) with respect to the pharmacy benefit management services provided to the plan or coverage; </text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id9383afc96eec4afeb7091586a2753498"><enum>(3)</enum><text display-inline="yes-display-inline">nothing would be construed to prohibit entities providing pharmacy benefits management services from retaining bona fide service fees in accordance with the requirements of section 408(b)(2) of the Employee Retirement Income Security Act of 1974 (<external-xref legal-doc="usc" parsable-cite="usc/29/1108">29 U.S.C. 1108(b)(2)</external-xref>); and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="ida616344c33b04980b863ab38a6e3a39a"><enum>(4)</enum><text display-inline="yes-display-inline">bona fide service fees would be per se unreasonable for purposes of this section and such section if such fees are—</text><subparagraph commented="no" display-inline="no-display-inline" id="id4e8bde973fe849f6a993b9e8d1877b57"><enum>(A)</enum><text display-inline="yes-display-inline">based on drug price (such as wholesale acquisition cost) or drug benchmark price (such as average wholesale price); </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id6478f2c939ed4317a71a3b1289c0f54b"><enum>(B)</enum><text display-inline="yes-display-inline">discounts, rebates, fees, or other remuneration with respect to prescription drugs prescribed to participants or beneficiaries in the plan or coverage; or</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id90d9927bc858443d8c1073a938655cd7"><enum>(C)</enum><text display-inline="yes-display-inline">otherwise determined by the Secretary to be unreasonable.</text></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="idee58958d87264f12a21c1e9854f50785"><enum>(c)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text><paragraph id="idce968577afdf4f9684074b470b6bb530"><enum>(1)</enum><header>Bona fide service fees</header><text>The term <term>bona fide service fees</term> means fees paid by a manufacturer, customer, or client (other than a group health plan or health insurance issuer) of an entity providing pharmacy benefit management services, to an entity providing pharmacy benefit management services, that represent fair-market value for bona fide, itemized services actually performed on behalf of the manufacturer, customer, or client and that the manufacturer, customer, or client would otherwise perform or contract for in the absence of the service arrangement, and that are not passed on in whole or in part to a client or customer of an entity, whether or not the entity takes possession of the drug. </text></paragraph><paragraph id="id0fae312db8224258bfc1faa47dff6710" commented="no" display-inline="no-display-inline"><enum>(2)</enum><header>Wholesale acquisition cost</header><text>The term <term>wholesale acquisition cost</term> has the meaning given such term in section 1847A(c)(6)(B) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)(B)).</text></paragraph></subsection></section></legis-body></bill> 

